Nearly 450 Medicines in Development For Neurological Disorders - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Nearly 450 Medicines in Development For Neurological Disorders



America’s biopharmaceutical research companies are developing 444 new medicines to prevent and treat neurological disorders, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA).

More than 600 neurological disorders, ranging from well-known disorders such as epilepsy, multiple sclerosis and Parkinson’s disease, to more obscure conditions such as Duchenne muscular dystrophy and Friedreich's ataxia,  strike millions of Americans each year.

These potential medicines, all in human clinical trials or under review by FDA include:

82 medicines for Alzheimer’s disease, which afflicts more than 5 million Americans
82 for pain;  100 million US adults experience chronic pain
62 for brain tumors; nearly 70,000 Americans are diagnosed each year with a primary brain tumor
38 for multiple sclerosis, which afflicts an estimated 500,000 Americans
25 for headache, including migraine, a condition that affects more than 37 million Americans
28 for epilepsy and seizures, which impacts more than 3 million Americans
27 for Parkinson’s disease, which affects as many as 1 million Americans

Of the 444 medicines in development, many represent novel, exciting scientific approaches to target diseases, such as a gene therapy to restore neuronal function in Alzheimer’s patients, targeted therapies for neuromuscular disorders and gene therapy to restore cells damaged in Parkinson’s patients.

Source: PhRMA

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns

Click here